市場調査レポート

商品コード

1722413

ヘモグロビン異常症市場レポート：タイプ別、治療別、検査タイプ別、エンドユーザー別、地域別、2025年～2033年

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2025-2033

出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 437,284円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 583,094円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 728,904円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.81円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ヘモグロビン異常症の世界市場規模は2024年に110億米ドルに達しました。今後、IMARC Groupは、2033年には222億米ドルに達し、2025～2033年の成長率（CAGR）は8.16%になると予測しています。製薬会社、ヘルスケアプロバイダー、研究機関の戦略的提携やパートナーシップの増加、個別化医療へのシフトの高まり、規制当局の支援や有利な償還政策の実施などが、市場成長を促進する主な要因の1つです。

ヘモグロビン異常症のは、ヘモグロビン分子に影響を及ぼす遺伝子疾患群であり、全身に酸素を運ぶ赤血球の適切な機能に極めて重要です。これらの疾患は主に、サラセミアと鎌状赤血球貧血のような異常ヘモグロビン変異型の2種類に分類されます。サラセミアは、ヘモグロビンを構成するグロビン鎖の1本の産生量が減少する突然変異に起因し、バランスが崩れて貧血になります。一方、鎌状赤血球貧血のような疾患は、ヘモグロビン分子自体の形や機能に異常をきたす突然変異によって引き起こされます。異常な形状により赤血球が硬くなり、細い血管を通りにくくなるため、酸素の分配に影響を及ぼします。ヘモグロビン異常症は遺伝性であることが多く、疲労、脱力感、ひどい場合には臓器障害など、軽度から重度までさまざまな症状を引き起こします。

一般市民の意識の高まりが、世界市場を大きく牽引しています。ヘモグロビン異常症のに焦点をあてた組織は、政策変更、資金調達、患者ケアの改善を求めるロビー活動でますます効果を上げています。また、一般市民への啓蒙活動も重要であり、それによって早期診断と治療が増加します。ヘルスケアシステムがより強固で利用しやすくなるにつれて、ヘモグロビン異常症のような専門的な疾患を診断・治療する能力も高まっています。新たな診療所や病院には高度な診断技術が導入され、より多くの患者に対応できるようになっています。これとともに、製薬会社、ヘルスケアプロバイダー、研究機関の戦略的提携やパートナーシップも、ヘモグロビン異常症の産業の成長を後押ししています。さらに、個別化医療が重視されるようになっていることも、ヘモグロビン異常症の市場にプラスの影響を与えている要因の1つです。個別化医療とは、個々の患者の特性に合わせた治療を行うことです。個別化医療へのシフトは、専門的な診断検査や治療の需要に影響を与え、市場の成長をさらに促進しています。さらに、規制当局の支援や有利な償還政策の実施により、市場の見通しは明るいです。

ヘモグロビン異常症の市場動向と促進要因：

ヘモグロビン障害の有病率の増加

ヘモグロビン異常症の業界を牽引する最も重要な要因の1つは、鎌状赤血球貧血、サラセミア、その他の希少変異型などのヘモグロビン障害の有病率の上昇です。これらの疾患は特定の民族集団や地域で流行しているが、世界の移民パターンにより、より広範な人口に見られるようになってきています。歴史的に罹患率の低かった国々でも、現在では多くの症例が報告されるようになり、これらの疾患を管理するためのヘルスケア・インフラの改善が必要となっています。認知度が高まり、診断率が上昇するにつれて、専門的な治療、診断、管理計画に対する需要も増加しています。さらに、より多くのヘルスケアプロバイダーがヘモグロビン異常症のを認識し治療するためのトレーニングを受けており、市場の成長をさらに促進しています。これらすべての要因が、ヘモグロビン異常症のに合わせた投薬、診断機器、遺伝子検査キット、専門的ヘルスケアサービスに対するニーズの増加に寄与し、業界の成長を促進しています。

診断と治療における技術の進歩

ヘモグロビン異常症の産業のもう一つの重要な推進力は、診断方法と治療の両方における技術の進歩です。新生児スクリーニングによる早期診断や、高速液体クロマトグラフィー（HPLC）や分子生物学的手法を含む高度な診断ツールは、病態のより良い管理につながっています。これとともに、遺伝子治療、CRISPR技術、薬剤製剤の改良などの治療法の進歩も、ヘモグロビン異常症のより効果的な管理に道を開いています。こうした技術革新は、患者の予後を向上させるだけでなく、市場関係者が研究開発に投資する原動力にもなっています。技術の進化に伴い、より正確で迅速な診断ツールや、潜在的に治癒可能な治療法の登場が予想され、業界の需要拡大と拡大が促進されます。

政府の取り組みと資金調達

政府の取り組みもヘモグロビン異常症の業界にとって重要な市場促進要因です。世界中の様々な政府が、ヘモグロビン異常症が公衆衛生に与える影響を認識するようになっており、ヘモグロビン異常症に対処するための的を絞ったプログラムを立ち上げつつあります。さらに、調査への資金提供、一般市民への啓発キャンペーン、国家ヘルスケア計画へのヘモグロビン異常症スクリーニングの組み入れは、そのような取り組みの一例です。こうした措置は、診断率を高めるだけでなく、より多くの人々が治療を受けやすくします。また、製薬会社や研究機関が治療法を開発するための特別助成金や財政支援も用意されています。このような取り組みやこの分野への資金投入は、需要と供給の両方を大幅に強化し、市場の成長を促進します。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Bio-Rad Laboratories Inc.
- bluebird bio Inc.
- Bristol-Myers Squibb Company
- Danaher Corporation
- Emmaus Life Sciences Inc.
- Gamida-Cell Ltd.
- Global Blood Therapeutics Inc.
- Novartis AG
- PerkinElmer Inc.
- Pfizer Inc.
- Prolong Pharmaceuticals LLC
- Sangamo Therapeutics Inc.
- Sysmex Corporation

図表

List of Figures

Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2024
Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2024
Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2024
Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2024
Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2024
Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2024
Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million USD), 2025-2033
Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million USD), 2025-2033
Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million USD), 2025-2033
Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Hemoglobinopathies Market: Competitive Structure
Table 8: Global: Hemoglobinopathies Market: Key Players

Product Code: SR112025A5123

The global hemoglobinopathies market size reached USD 11 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 8.16% during 2025-2033. The rising strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions, the growing shift toward personalized medicine, and the implementation of regulatory support and favorable reimbursement policies are among the key factors driving the market growth.

Hemoglobinopathies are a group of genetic disorders that affect the hemoglobin molecule, which is crucial for the proper function of red blood cells in carrying oxygen throughout the body. These disorders can be categorized mainly into two types: thalassemias and abnormal hemoglobin variants, such as sickle cell anemia. Thalassemias result from mutations that reduce the production of one of the globin chains that make up hemoglobin, leading to an imbalance and subsequent anemia. On the other hand, conditions such as sickle cell anemia are caused by mutations that lead to abnormal shapes or functions of the hemoglobin molecule itself. The abnormal shapes can cause red blood cells to become rigid, making it difficult for them to travel through small blood vessels, thereby affecting oxygen distribution. They are often inherited and can result in symptoms ranging from mild to severe, including fatigue, weakness, and in extreme cases, organ damage.

The growing public awareness majorly drives the global market. Organizations focused on hemoglobinopathies are increasingly effective at lobbying for policy changes, funding, and improved patient care. They are also crucial in educating the public, thereby increasing early diagnosis and treatment. As healthcare systems become more robust and accessible, the capability to diagnose and treat specialized conditions, such as hemoglobinopathies also increases. New clinics and hospitals are being equipped with advanced diagnostic technologies, thereby reaching a larger patient population. Along with this, strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions are also driving the growth of the hemoglobinopathies industry. In addition, the growing emphasis on personalized medicine is another factor that impacts the hemoglobinopathies market positively. Personalized medicine involves tailoring medical treatment to individual patient characteristics. The shift toward personalized medicine is influencing the demand for specialized diagnostic tests and treatments, further driving market growth. Moreover, the implementation of regulatory support and favorable reimbursement policies is creating a positive market outlook.

Hemoglobinopathies Market Trends/Drivers:

Increasing prevalence of hemoglobin disorders

One of the most significant drivers propelling the hemoglobinopathies industry is the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemias, and other rare variants. These disorders are prevalent in specific ethnic groups and geographical regions, but due to global migration patterns, they are increasingly found in a more widespread population. Countries with historically low incidence rates are now reporting more cases, necessitating improved healthcare infrastructure to manage these conditions. As awareness grows and diagnosis rates increase, there is a corresponding rise in demand for specialized treatments, diagnostics, and management plans. Additionally, more healthcare providers are being trained to recognize and treat hemoglobinopathies, further facilitating market growth. All these factors contribute to increased needs for medication, diagnostics equipment, genetic testing kits, and specialized healthcare services tailored for hemoglobinopathies, thereby driving the industry's growth.

Technological advancements in diagnosis and treatment

Another significant driver for the hemoglobinopathies industry is the technological advancements in both diagnostic methods and treatments. Earlier diagnosis through newborn screenings and sophisticated diagnostic tools including High-Performance Liquid Chromatography (HPLC) and molecular techniques have led to better management of the condition. Along with this, advancements in treatment methods, including gene therapy, CRISPR technology, and improved drug formulations, are also paving the way for more effective management of hemoglobin disorders. These innovations not only enhance patient outcomes but also provide an impetus for market players to invest in research and development. As the technology evolves, we can anticipate more accurate, quicker diagnostic tools and potentially curative therapies, driving greater demand and expansion in the industry.

Government Initiatives and Funding

Governmental efforts are also significant market drivers for the hemoglobinopathies industry. Various governments worldwide are increasingly acknowledging the public health impact of hemoglobin disorders and are setting up targeted programs to deal with them. In addition, funding for research, public awareness campaigns, and inclusion of hemoglobinopathy screening in national healthcare plans are examples of such initiatives. These steps not only increase the rate of diagnosis but also make treatments more accessible to a larger population. Special grants and financial support for pharmaceutical companies and research institutions for developing treatments are also available. Such initiatives and financial injections into the sector significantly bolster both demand and supply, facilitating market growth.

Hemoglobinopathies Industry Segmentation:

Breakup by Type:

Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
Sickle Cell Disease
Others

Sickle cell disease accounts for the majority of the market share

The market for treating sickle cell disease (SCD), a type of hemoglobinopathy, is experiencing robust growth due to the rising incidence and awareness of SCD, particularly in African, Middle Eastern, and South Asian populations. Additionally, advancements in diagnostic techniques, including high-performance liquid chromatography (HPLC) and genetic screening are enabling earlier and more accurate detection, increasing the demand for targeted treatments. In addition, government initiatives have also played a pivotal role by incorporating SCD screenings in national healthcare plans and providing funding for research. In addition, the emergence of innovative treatment options such as gene therapies and CRISPR technology offer potential curative solutions, attracting significant investment in the sector. Furthermore, positive regulatory frameworks and reimbursement policies make treatments more accessible, thereby expanding the market.

Breakup by Treatment:

Blood Transfusion
Stem-cell Transplantation
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others

The demand for blood transfusion treatment in the hemoglobinopathies industry is primarily driven by its essential role in managing severe cases of disorders, such as thalassemia and sickle cell disease. Along with this, the increasing prevalence of these conditions amplifies the need for regular transfusions, thereby fueling market growth. In addition, technological advancements in blood screening and storage have also contributed to safer and more efficient transfusion processes. Governmental initiatives, such as organized blood donation campaigns and reimbursement policies, make this treatment more accessible and cost-effective for patients. In addition, the growing interest in stem-cell transplantation as a potentially curative treatment for hemoglobinopathies, including thalassemia and sickle cell disease is a notable market driver. Moreover, technological advancements have made these procedures safer and more effective, drawing increased investment and research focus. Governmental backing in the form of grants and regulatory approval fast-tracks also bolster this sector.

On the other hand, the growing awareness and advocacy for advanced treatment options have led to higher demand for stem-cell transplantation, further propelling market growth in the hemoglobinopathies industry. Apart from this, the demand for analgesics in the hemoglobinopathies industry is driven by chronic pain. Increasing awareness and diagnosis rates further provide a boost to this market segment. The need for antibiotics in the hemoglobinopathies industry is driven by frequent bacterial infections in patients, thereby stimulating the demand for effective treatment options. Furthermore, the market for ACE inhibitors in the hemoglobinopathies industry is propelled by their role in managing kidney complications in patients.

Breakup by Test Type:

Red Blood Cell (RBC) Count
Genetic Testing
High Performance Liquid Chromatography (HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin Electrophoresis (Hb ELP)
Hemoglobin Solubility Test

In the hemoglobinopathies industry, the market drivers for the red blood cell (RBC) count test type are significant. Hemoglobinopathies, including conditions, such as sickle cell anemia and thalassemia, necessitate frequent monitoring of RBC counts to assess disease severity and treatment efficacy. As awareness of these disorders grows, so does the demand for accurate diagnostic tools. Moreover, advancements in healthcare technology have led to more accessible and cost-effective RBC count testing methods. The combination of increased disease awareness and improved diagnostic capabilities positions the RBC count test as a critical component of the hemoglobinopathies industry, driving its market growth. Along with this, genetic testing is a key market driver in the hemoglobinopathies industry, enabling precise disease identification and personalized treatment strategies, and fostering growth and innovation.

On the other hand, high-performance liquid chromatography (HPLC) is a crucial driver in the hemoglobinopathies industry, providing precise hemoglobin analysis, enhancing diagnostics, and fostering industry advancement. Apart from this, hemoglobin isoelectric focusing (Hb IEF) plays a pivotal role in the hemoglobinopathies industry by offering precise hemoglobin analysis, driving diagnostic accuracy, and industry growth. In confluence with this, hemoglobin electrophoresis (Hb ELP) is a cornerstone in the hemoglobinopathies industry, providing precise hemoglobin analysis, driving diagnostic accuracy, and fostering industry growth. Furthermore, hemoglobin solubility testing is a critical driver in the hemoglobinopathies industry, offering efficient diagnosis and aiding in disease management, contributing to industry growth.

Breakup by End User:

Hospitals and Clinics
Diagnostics Laboratories
Others

Diagnostics laboratories serve as a pivotal end user in the hemoglobinopathies industry, driving growth due to their central role in disease diagnosis and management. In addition, the increasing prevalence of hemoglobinopathies worldwide necessitates a higher volume of diagnostic tests, including hemoglobin analysis and genetic testing. Furthermore, ongoing research and development efforts focus on enhancing the accuracy and efficiency of diagnostic tools, further elevating the significance of diagnostics laboratories. Their expertise and technology contribute significantly to advancing our understanding of hemoglobin disorders and tailoring treatment approaches, solidifying their status as key market drivers in this industry.

On the contrary, hospitals and clinics represent crucial end users in the hemoglobinopathies industry, actively driving growth and advancement. These healthcare facilities are frontline providers of care to individuals affected by hemoglobin disorders. The growing awareness of these conditions, coupled with an increasing patient population, leads to a higher demand for diagnostic tests, genetic counseling, and specialized treatments. Hospitals and clinics play a pivotal role in providing comprehensive care, driving the need for improved diagnostic tools and therapeutic interventions. Their prominence as end users reinforces their impact as significant market drivers in the hemoglobinopathies industry.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America leads the market, accounting for the largest hemoglobinopathies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America stands as a dynamic and influential region in the hemoglobinopathies industry, driven by the region's commitment to healthcare excellence and rigorous standards. It fuels the demand for cutting-edge diagnostic tools and therapeutic interventions. The prevalence of hemoglobin disorders, particularly sickle cell disease, within diverse populations, including African Americans and Hispanic communities, places North America at the forefront of research, diagnosis, and treatment.

Additionally, the region's robust research and development ecosystem, consisting of academic institutions, pharmaceutical companies, and biotechnology firms, fosters innovation in hemoglobinopathy diagnostics and therapies. This research-driven environment continually introduces novel diagnostic methods and treatment modalities, stimulating market growth. Furthermore, advocacy efforts and government initiatives aimed at improving healthcare access for individuals with hemoglobinopathies amplify the demand for diagnostic testing and specialized care. These initiatives include newborn screening programs and policies supporting early diagnosis and intervention.

Competitive Landscape:

The key players are investing heavily in research and development to discover new diagnostic tests, therapies, and treatment modalities. They aim to enhance the accuracy of diagnostic tools and develop innovative treatments that can improve the quality of life for individuals with hemoglobin disorders. Along with this, companies are continually developing and improving diagnostic tests for hemoglobinopathies, including advancements in techniques, such as genetic testing, high-performance liquid chromatography (HPLC), hemoglobin electrophoresis (Hb ELP), and hemoglobin isoelectric focusing (Hb IEF) is positively influencing the market. In addition, pharmaceutical companies in the hemoglobinopathies market work on the development of new therapies, including gene therapies, gene editing technologies (e.g., CRISPR), and small molecule drugs, which act as another growth-inducing factor. Furthermore, the widespread adoption of cutting-edge technologies, such as artificial intelligence and machine learning, for data analysis and improving diagnostic accuracy is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Bio-Rad Laboratories Inc.
bluebird bio Inc.
Bristol-Myers Squibb Company
Danaher Corporation
Emmaus Life Sciences Inc.
Gamida-Cell Ltd.
Global Blood Therapeutics Inc.
Novartis AG
PerkinElmer Inc.
Pfizer Inc.
Prolong Pharmaceuticals LLC
Sangamo Therapeutics Inc.
Sysmex Corporation

Key Questions Answered in This Report

1.What was the size of the global hemoglobinopathies market in 2024?
2.What is the expected growth rate of the global hemoglobinopathies market during 2025-2033?
3.What has been the impact of COVID-19 on the global hemoglobinopathies market?
4.What are the key factors driving the global hemoglobinopathies market?
5.What is the breakup of the global hemoglobinopathies market based on the type?
6.What is the breakup of the global hemoglobinopathies market based on the treatment?
7.What are the key regions in the global hemoglobinopathies market?
8.Who are the key players/companies in the global hemoglobinopathies market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Hemoglobinopathies Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Thalassemia
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Alpha Thalassemia
  - 6.1.2.2 Beta Thalassemia
- 6.1.3 Market Forecast
6.2 Sickle Cell Disease
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Treatment

7.1 Blood Transfusion
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Stem-cell Transplantation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Analgesics
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Antibiotics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 ACE Inhibitors
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Hydroxyurea
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast

8 Market Breakup by Test Type

8.1 Red Blood Cell (RBC) Count
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Genetic Testing
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 High Performance Liquid Chromatography (HPLC)
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Hemoglobin Electrophoresis (Hb ELP)
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Hemoglobin Solubility Test
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals and Clinics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Diagnostics Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Bio-Rad Laboratories Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 bluebird bio Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Bristol-Myers Squibb Company
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Danaher Corporation
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Emmaus Life Sciences Inc.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Gamida-Cell Ltd.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
- 15.3.7 Global Blood Therapeutics Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
- 15.3.8 Novartis AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 PerkinElmer Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Prolong Pharmaceuticals LLC
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
- 15.3.12 Sangamo Therapeutics Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis
- 15.3.13 Sysmex Corporation
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis

ヘモグロビン異常症市場レポート：タイプ別、治療別、検査タイプ別、エンドユーザー別、地域別、2025年～2033年

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2025-2033

ヘモグロビン異常症の市場動向と促進要因：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のヘモグロビン異常症市場

第6章 市場内訳：タイプ別

第7章 市場内訳：治療別

第8章 市場内訳：検査タイプ別

第9章 市場内訳：エンドユーザー別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢